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Abstract
Objective—The goal of the present study was to identify novel mechanisms that regulate SMC 
differentiation marker gene expression.
Approach and Results—We demonstrate that the CArG-containing regions of many SMC-
specific promoters are imbedded within CpG islands. A previously identified GC repressor 
element in the SM MHC promoter was highly methylated in cultured aortic SMC but not in the 
aorta and this difference was inversely correlated with SM MHC expression. Using an affinity 
chromatography/mass spectroscopy-based approach, we identified the multifunctional Notch 
transcription factor, RBPJ/CSL1, as a methylated GC-repressor binding protein. RBPJ protein 
levels and binding to the endogenous SM MHC GC repressor were enhanced by PDGF-BB 
treatment. A methylation mimetic mutation to the GC repressor that facilitated RBPJ binding 
inhibited SM MHC promoter activity as did over-expression of RBPJ. Consistent with this, 
knockdown of RBPJ in phenotypically modulated human aortic SMC enhanced endogenous SMC 
marker gene expression, an effect likely mediated by increased recruitment of SRF and Pol II to 
the SMC-specific promoters. In contrast, depletion of RBPJ in differentiated TGF-β-treated SMC 
inhibited SMC-specific gene activation supporting the idea that the effects of RBPJ/Notch 
signaling are context dependent.
Conclusions—Our results indicate that methylation-dependent binding of RBPJ to a GC 
repressor element can negatively regulate SM MHC promoter activity and that RBPJ can inhibit 
SMC marker gene expression in phenotypically modulated SMC. These results will have 
important implications on the regulation of SMC phenotype and on Notch-dependent 
transcription.
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It has been well established that SRF and the myocardin family of SRF co-factors mediate 
SMC-specific transcription by interacting with conserved CArG elements within the 
promoters of the SMC differentiation marker genes 1. However, since these transcription 
factors are expressed in many non-SMC sub-types 2, it is clear that additional mechanisms 
are also critical for the overall pattern of SMC-specific gene expression observed in vivo.
One mechanism that is likely to be important in the regulation of SMC-specific transcription 
is modification of chromatin structure. Histone modifications that favor gene expression (i.e. 
H3 and H4 acetylation, H3K4 methylation, H3K9 demethylation/acetylation) have been 
observed at the SMC-specific promoters in SMC 3–7. In addition, we and others have shown 
that the myocardin factors can facilitate chromatin modification by recruiting histone 
modifying enzymes 5, 8–12.
Another epigenetic mechanism that has received less attention in regard to its effects on 
SMC-specific transcription is DNA methylation. This epigenetic mark is predominantly 
associated with gene silencing and has been shown to be important for a wide variety of 
cellular functions including genomic imprinting, X-inactivation, cellular differentiation, and 
carcinogenesis (see 13 for review). DNA methylation is catalyzed by a family of DNA 
methyltransferases and typically occurs on cytosines at the 5 position of the pyrimidine ring 
and in the context of CpG dinucleotides (C followed by G). The majority of CpGs within the 
genome are dispersed and methylated. However, many gene promoters, especially those of 
highly expressed house-keeping genes, contain regions of high CpG content known as CpG 
islands that are typically unmethylated. Methylated cytosines are thought to suppress gene 
expression by sterically inhibiting transcription factor binding to cis regulatory elements or 
by associating with methyl binding domain-containing proteins (MBDs1-4, MeCP2, Kaiso) 
that recruit additional transcription repressors. Interestingly, DNA regions that are heavily 
methylated are also associated with high levels of tri-methyl H3K9, and these negative 
chromatin marks act cooperatively by the reciprocal recruitment of their respective 
methyltransferases (see 14 for review).
Based upon our previous demonstration that H3K9 methylation status at the CArG-
containing regions of the SMC-specific promoters was an important determinant of SMC 
differentiation marker gene expression 8, we hypothesized that DNA methylation may also 
play a role. Our results indicate that methylation of a GC repressor in the SM MHC 
promoter inversely correlates with SM MHC expression in aortic SMC, that the methylated 
GC repressor recruits the multifunctional transcription factor RBPJ/CSL-1, and that RBPJ 
can inhibit SMC marker gene expression in phenotypically modulated human aortic SMC.
MATERIELS AND METHODS
Detailed methods can be found in the on-line supplement.
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SM MHC expression in SMC inversely correlates with promoter methylation
To begin to examine whether DNA methylation plays a role in the regulation of SMC-
specific gene expression, we searched for CpG islands within the SMC differentiation 
marker gene promoters using the formal definition (sequence of at least 200 bp in length, a 
GC content of greater than 50%, and an observed-to-expected CpG ratio greater than 60%). 
In both human and mouse, the CArG-containing regions shown to be important for SM 
MHC, SM22, and calponin expression were imbedded within CpG islands suggesting that 
methylation might regulate the SRF/Myocardin factor-dependent activation of these genes. 
We used standard bisulphite sequencing to measure CpG island methylation within the 
SM22 and SM MHC promoters in primary mouse aortic SMC cultures and in mouse 10T1/2 
cells, a pluripotent line frequently used as a SMC precursor. As shown in Figure 1a, the CpG 
island within the SM22 promoter was highly methylated in 10T1/2 cells but almost 
completely unmethylated in SMC. This result correlates well with SM22 expression levels 
in these cell-types and suggests that promoter methylation may play a role in the regulation 
of SM22 expression. The CpG island within the proximal SM MHC promoter was also 
highly methylated in 10T1/2 cells (Fig 1b). However, we also detected significant 
methylation of the SM MHC promoter in SMC. Since the SM MHC gene is the first 
differentiation marker to be down-regulated in phenotypically modulated SMC, we 
hypothesized that the observed methylation of the SM MHC promoter reflected phenotypic 
modulation of our cultured SMC. To test this idea, we measured SM MHC promoter 
methylation in freshly isolated aortic media following removal of the adventitial and 
endothelial cell layers by collagenase/elastase digestion and microdissection. The SM MHC 
CpG island was completely unmethylated in aortic medial SMC in vivo, and this result 
correlated with much stronger expression of SM MHC as measured by Western blotting of 
lysates prepared from the same samples (Fig 1c).
Several CpGs within the SM MHC promoter were almost completely methylated in cultured 
SMC. One of these was present within a GC-rich sequence just down-stream of CArG2 that 
had been previously characterized as a repressor element 15. Deletion of a similar but not 
identical GC repressor within the SM22 promoter prevented the down-regulation of SM22 
promoter activity that occurs following vessel injury 16, 17. The GC repressor within the SM 
MHC promoter was also fully methylated in mouse EC (data not shown) perhaps suggesting 
that this mechanism is important for the repression of SM MHC expression in other cell-
types in the vessel wall.
Because the effects of promoter methylation are thought to be mediated by alterations in 
protein-DNA binding, we performed gel shift analyses with methylated and unmethylated 
mouse SM MHC GC repressor probes and nuclear extracts isolated from SMC cultures. 
Importantly, the major protein complex that bound to the methylated GC repressor did not 
bind to the unmethylated probe (Fig 1d, compare lanes 1 and 4). In addition, complex 
binding to the methylated repressor was increased when extracts were prepared from cells 
treated with PDGF-BB, an agonist known to down-regulate SMC differentiation marker 
gene expression. In contrast, treatment of cells with TGF-b whih activates SMC 
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differentiation marker gene expression had little effect on complex formation. To better 
examine the formation of this methylation-dependent complex in vivo, we performed gel 
shift assays using nuclear extracts prepared from control and wire-injured carotid arteries. A 
similar methylation-dependent binding complex was detected and was significantly 
increased in extracts prepared from injured arteries (Fig 1d compare lanes 7 and 8). We 
initially hypothesized that this complex contained one of the known methylated DNA 
binding proteins but we were unable to supershift this band with antibodies to these factors. 
Several additional bands were detected in some gel shift assays, but these were either not 
methylation-dependent or were mostly non-specific (Fig 2 and data not shown).
The methylated SM MHC GC repressor binds RBPJ
We next used agarose beads conjugated to the methylated GC repressor to affinity purify the 
methylation-dependent protein binding complex from SMC nuclear extracts. Proteins that 
precipitated with the methylated, but not the unmethylated probe were cut out of SDS page 
gels and sent for mass spec analysis. Each of three separate experiments identified the 
multifunctional Notch transcription factor, RBPJ, as a methylated GC repressor binding 
protein. Additional gel shifts demonstrated that the major complex that bound the 
methylated GC repressor was similar to that formed when using a consensus RBPJ 
oligonucleotide probe (Fig 2a; compare lanes 1 and 5). Moreover, addition of an RBPJ 
antibody to gel shift reactions resulted in a complete super-shift providing conclusive 
evidence for the presence of RBPJ in this complex (Figure 2a; compare lanes 1 and 2). As 
shown in Figure 2b, RBPJ binding to the methylated GC repressor was specific in that it was 
completely abolished by addition of cold methylated probe (or the consensus RBPJ element) 
but not by cold unmethylated probe.
Notch signaling plays an important role in vascular development and maintenance by 
regulating cell fate decisions in both EC and SMC (see 18 for review). Activation of the 
integral membrane Notch receptors by Delta-like or Jagged ligands results in proteolytic 
cleavage of the receptor by γ-secretase, release of the Notch intracellular domain (NICD), 
and translocation of the NICD to the nucleus where it interacts with RBPJ. In the absence of 
NICD, RBPJ binds a consensus site (GTGGGA) within the promoters of Notch target genes 
and has been shown to inhibit gene expression by recruiting HDACs and other 
transcriptional repressors. NICD binding to RBPJ displaces the repressive factors (resulting 
in derepression) but also aids in the recruitment of additional transcription activators. 
Although Notch signaling has been shown to be required for SMC differentiation of neural 
crest cells, epicardial cells, or Tie1-expressing progenitor cells 19–21, the direct effects of 
Notch/RBPJ signaling on SMC differentiation marker gene expression are relatively 
weak 22–24, are significantly complicated by feedback inhibition mediated by the Notch 
target genes, Hes and Hey (see 25 for review), and are context dependent with several 
studies showing both positive and negative effects 22–24, 26–28.
Characterization of RBPJ binding to methylated DNA
We noted that the reverse strand of the GC-rich element (GCGGGA) differed from the 
consensus core RBPJ binding site by only one base-pair, a thymine to cytosine substitution. 
Additional gel shift assays with hemi-methylated probes demonstrated that only methylation 
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of the reverse strand was required for RBPJ binding (Fig 3a). Since the pyrimidine ring of 
thymine is constitutively methylated at the 5′ position (Fig 3b), we hypothesized that 
methylation of cytosine conferred enough structural similarity between these nucleotides to 
facilitate RBPJ binding. Supporting this idea, a GC repressor containing a cytosine to 
thymine substitution was shown to interact with RBPJ (Fig 3c, lane 3). Conversely, RBPJ 
did not bind well to a consensus sequence in which the thymine was replaced by cytosine, 
but did bind strongly to a consensus probe in which the thymine was replaced with a 
methylated cytosine (Fig 3c, compare lanes 7 and 6).
The crystal structure of RBPJ bound to its consensus DNA element has been solved 29, 30. 
Several conserved polar amino acids in the RBPJ DNA binding pocket (especially Arg 65) 
were shown to interact with the 3 central guanine residues at least partially explaining the 
specificity of RBPJ binding to the consensus sequence. Interestingly, no such interactions 
were detected for the consensus thymine supporting our contention that binding specificity 
at this residue is mediated by the presence of a methyl group at the pyrimidine 5′ position. 
Although Glu63 is the nearest amino acid to this thymine residue, the 5′ methyl group is 
positioned closer to the carbon backbone of the glutamate side-chain than to the polar head 
group. As shown in figure 3d, a conservative Glu63Asp mutation almost completely 
inhibited RBPJ binding to the consensus probe and the same probe in which the thymine 
was replaced by methylated cytosine. Taken together, these data strongly suggest that the 
positioning of the carboxyl group of Glu63 is critical for the formation of a methyl binding 
pocket that stabilizes the RBPJ-DNA interaction.
RBPJ negatively regulates SM MHC promoter activity
We next used several gain-of-function/loss-of-function approaches to examine the effects of 
RBPJ on SMC-specific promoter activity. As shown in figure 4a, over-expression of RBPJ 
in 10T1/2 cells significantly inhibited the activities of multiple SMC-specific promoters in 
the presence of myocardin. We also established SMC cultures from RBPJflox/flox mice and 
used adenoviral-mediated expression of Cre recombinase to reduce RBPJ expression and 
DNA binding in these cells by approximately 85% (Fig 4b). Importantly, SM MHC 
promoter activity in SMC over-expressing myocardin was significantly higher in Cre versus 
LacZ infected SMC (Fig 4c). Although these results strongly suggest that RBPJ can function 
as an inhibitor in these contexts, the lack of reagents to the alter the methylation of specific 
CpGs has made it difficult to study the functional effects of this modification. However, our 
ability to promote RBPJ binding to the GC repressor by a thymine substitution that 
“mimics” cytosine methylation (see Figure 3c) allowed us to assess the functional 
significance of this interaction. A cytosine to thymine substitution within the GC repressor 
significantly attenuated myocardin-dependent SM MHC promoter activity supporting our 
hypothesis that methylation-dependent binding of RBPJ to the GC repressor inhibits SM 
MHC promoter activity. Chromatin immunoprecipitation (ChIP) assays in our mouse SMC 
cultures demonstrated that RBPJ binds to the endogenous SM MHC GC repressor (Fig 5a), 
and in excellent agreement with our gel shift assays, that this interaction was enhanced by 
PDGF-BB treatment. As shown in Fig 5b, PDGF-BB treatment increased RBPJ protein 
levels in both SMC and 10T1/2 cells. Given that methylation of the GC repressor is already 
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very high in our cultured SMC, this result likely explains the increase in RBPJ binding to the 
GC repressor in PDGF-BB-treated cells.
RBPJ has dual effects on SMC-specific expression
The ability of Notch to stimulate SMC differentiation has been attributed to the recruitment 
of the NICD to RBPJ binding sites within the SMC-specific promoters 22–24. However, our 
demonstration that RBPJ binds to methylated DNA, is up-regulated by PDGF-BB and vessel 
injury, and can inhibit SMC-specific promoter activity led us to hypothesize that RBPJ can 
also function as a repressor in phenotypically modulated SMC. To begin to test this idea we 
used siRNA to knockdown RBPJ in a human aortic SMC line that exhibits very low levels 
of the SMC marker genes under basal growth conditions but high levels when treated with 
TGF-β. As shown in Figure 6a, RBPJ binds to the CArG-containing regions of the SM 
MHC, SM α-actin, calponin, and SM22 genes in human aortic SMC and treatment of these 
cells with siRNA significantly inhibited RBPJ binding in this model. Importantly, depletion 
of RBPJ under growth conditions resulted in an increase in SMC marker gene mRNA levels 
suggesting that RBPJ functions as a repressor in this context (Figure 6b, undiff). Given the 
positioning of the GC repressor and other RBPJ binding sites to CArG elements in the SM 
MHC and other promoters 23, 24, we postulated that RBPJ might interfere with SRF binding 
under these conditions. Indeed, ChIP assays demonstrated that SRF binding to the SMC 
promoters was increased in RBPJ depleted cells (Fig 6c) even though SRF protein levels 
were not affected (suppl Figure I). Moreover, the increase in SMC marker gene mRNA in 
RBPJ knockdown cells was completely inhibited by co-depletion of SRF (Fig 6d). As 
expected, the positive effects of RBPJ depletion on SMC-specific gene expression and SRF 
binding were accompanied by the increased recruitment of RNA polymerase II.
In contrast, depletion of RBPJ from TGF-β treated human aortic SMC had an inhibitory 
effect on SMC-specific transcription. While SRF binding in these cells (which was much 
stronger than that observed under growth conditions) was mostly unchanged, RBPJ 
depletion strongly attenuated the presence of RNA polymerase II suggesting that recruitment 
of transcriptional cofactors or chromatin modifying enzymes was affected. In support of this 
idea, additional ChIP assays demonstrated that Notch3 binding (Fig 6e) and H3K9 
acetylation (Fig 6f) were decreased in RBPJ-depleted cells under these conditions.
DISCUSSION
The current studies indicate that methylation-dependent recruitment of RBPJ to a GC 
repressor element inhibits SM MHC promoter activity and that RBPJ can inhibit SMC 
differentiation marker gene expression in phenotypically modulated SMC by inhibiting SRF 
binding to the CArG-containing regions of the SMC-specific promoters. Interestingly RBPJ 
was required for full SMC marker gene activation in TGF-β-treated cells a result consistent 
with the requirement of Notch signaling for SMC differentiation in vivo19–21. It is likely that 
inhibition of NICD recruitment under these conditions decreased positive chromatin 
remodeling and Pol II binding leading to reductions in SMC marker gene expression. Taken 
together, our results support the current model of Notch signaling in which RBPJ inhibits 
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gene expression under unstimulated conditions, but is required for recruitment of the NICD 
and the positive transcriptional effects of Notch signaling.
Although DNA methylation can promote long-term and heritable gene inactivation 31, its 
role in the regulation of cell-type-specific gene expression is less clear 31–38 and may be 
related to the number and methylation status of CpGs within a particular promoter 38–40. 
Since de novo DNA methylation is catalyzed by DNA methyltranferases 3a and 3b, it will 
be important to identify the mechanisms by which these enzymes are recruited to the SM 
MHC promoter in cultured SMC. We have previously shown that H3K9 methylation at the 
CArG-containing regions of the SMC-specific promoters was associated with decreased SM 
MHC expression 8, and we are currently investigating whether this histone modification 
precedes and/or promotes SM MHC promoter methylation. Another interesting question is 
whether changes in DNA methylation regulate SMC-specific gene expression more acutely. 
We observed modest reductions in SM MHC promoter methylation during TGF-β-induced 
up-regulation of SM MHC expression in 10T1/2 cells (see suppl Fig II). However, the 
known heterogeneity in these cells is a confounding factor and additional experiments in the 
subset of cells that up-regulate SM MHC expression will likely be required to demonstrate 
that SM MHC promoter methylation is responsive to TGF-β. The failure to identify a robust 
DNA demethylation regulatory pathway has also hindered our understanding of the temporal 
control of DNA methylation. Enzymes that facilitate the demethylation reaction have been 
identified 41, 42 suggesting that DNA methylation (like histone methylation) is more 
dynamic than previously thought 43. Several studies provide support for the idea that SMC 
differentiation marker gene expression is regulated by DNA methylation. For example, the 
decrease in SM22 expression observed in human SMCs treated with high phosphate was 
associated with increased SM22 promoter methylation 44 while SM22 methylation was 
decreased in multipotential adventitial cells that were induced to differentiate into SMC 45. 
Hu et al. has also shown that SM α-actin expression in fibroblasts inversely correlated with 
DNA methylation near the SM α-actin transcription start site 46.
Using an unbiased SILAC-based biochemical screen, Bartels et. al. were the first to show 
that RBPJ interacted with methylated DNA 47. Our data strongly confirm that RBPJ binds to 
the sequence, G(Cm/T)GGGA, and we have significantly extended this finding by providing 
functional significance to RBPJ’s interaction with methylated DNA and by identifying SM 
MHC as an in vivo target for this mechanism. It is currently unclear whether RBPJ interacts 
with other gene promoters through a methylation-dependent mechanism or whether RBPJ 
binding to a methylated versus unmethylated sequence results in different transcriptional 
outcomes. Our gel shift data indicate that the methylated GC repressor can support the 
formation of a RBPJ/Notch complex in vitro (suppl Fig III), but it is unknown whether 
RBPJ’s interaction with repressive cofactors is affected. Defining the relationship between 
multiple RBPJ binding sites within a single promoter will also be important. As shown in 
suppl Figure IV, we did not detect significant binding of RBPJ to the SM22 GC repressor in 
gel shift assays most likely because it does not conform to the consensus RBPJ binding site 
even when methylated. Recent studies indicated that the effects of the SM22 GC repressor 
are mediated by the pluripotency factor, KLF4 17, and it may be interesting to test whether 
KLF4 binding to this element is affected by DNA methylation status.
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Structural analyses of several zinc finger transcription factors that bind to methylated DNA 
identified a 5mCytosine-Arg-Guanine triad that mediates this interaction (see 48 for review), 
and our data strongly support this mechanism. In this model, hydrogen bonding of Arg65 
with the guanine residue at position 3 of the consensus RBPJ binding sequence promotes 
van der Waals contacts between the Arg65 guanidino carbon moiety and the methyl group 
of the nucleotide at position 2 (whether 5mC or T). Our data also suggest that Glu63 is 
important for RBPJ binding to DNA, a result in excellent agreement with a recent human 
genetic study that identified a Glu63Gly mutation in RBPJ that was casual for Adams-Oliver 
syndrome, a disease that affects limb and cranium formation 49. Interestingly, the 
methylated DNA binding proteins, Kaiso and Zfp57, have similarly positioned Glu 
residues 48 further supporting the idea that Glu63 is critical for RBPJ binding to the 
methylated pyrimidine ring.
Several recent studies have used ChIP seq analyses to identify RBPJ and Notch binding sites 
on a genome-wide level in T-lymphoblastic leukemia cells, mouse E13.5 neural cortices, 
and C2C12 cells 50–52. Although Notch/RBPJ binding to the SMC marker gene promoters 
was not detected in these assays, several interesting findings are worth noting. Many RBPJ-
only and Notch-only binding sites were identified suggesting that these transcription factors 
have independent effects and perhaps that Notch can be recruited to DNA by transcription 
factors other than RBPJ. In addition, Notch/RBPJ binding was a poor predictor of gene 
activation. In fact, only 3% of the genes that were shown to bind Notch exhibited significant 
expression changes upon Notch activation strongly suggesting that additional transcription 
mechanisms are important for regulating Notch/RBPJ-dependent gene expression. Finally, 
bioinformatic analysis of over-represented sequences in the RBPJ ChIP seq data set from 
neuronal cells failed to identify the consensus RBPJ element, but did identify a GC rich 
sequence similar to the GC repressor. Additional studies that also incorporate methylation 
status and changes in gene expression in knockout cells will be required to better 
characterize the extent to which promoter methylation regulates Notch/RBPJ-dependent 
gene activation and/or repression.
In summary, our results indicate that RBPJ can inhibit SMC marker gene expression in 
phenotypically modulated SMC and that methylation-dependent recruitment of RBPJ may 
facilitate this repressive mechanism. These results have significant implications on our 
understanding of RBPJ/Notch-dependent regulation of cardiovascular development and 
disease and support further characterization of this mechanism and its consequences.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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SRF serum response factor
MRTF myocardin-related transcription factor
SMC smooth muscle cell
EC endothelial cell
MHC myosin heavy chain
RBPJ recombination signal binding protein for immunoglobulin kappa J region
NICD Notch intracellular domain
PDGF platelet-derived growth factor
TGF transforming growth factor
ChIP chromatin immunoprecipitation
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We show for the first time that methylation of a GC repressor in the SM MHC promoter 
inversely correlates with SM MHC expression in aortic SMC, that the methylated GC 
repressor recruits the multifunctional transcription factor RBPJ/CSL-1, and that RBPJ 
can inhibit SMC marker gene expression in phenotypically modulated human aortic 
SMC. These results have important implications on the regulation of SMC-specific and 
Notch/RBPJ-dependent gene expression.
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Figure 1. A GC repressor element in the mouse SM MHC promoter is methylated in cultured 
SMC
Schematic of CpG island methylation within the CArG-containing regions of the SM22 (A) 
and SM MHC (B) promoters as determined by bisulphite sequencing of genomic DNA 
isolated from 10T1/2 cells, mouse aortic SMC cultures, and mouse aorta. C) Western Blot 
for SM MHC expression in the indicated cells and tissues. D) The indicated radiolabeled 
mouse SM MHC GC repressor probes were incubated with nuclear extracts prepared from 
mouse aortic SMC treated for 24h with vehicle, PDGF-BB (20ng/ml), or TGF-β (1ng/ml) 
and from control (Ctl) or injured (Inj) femoral arteries. After 30 min, reactions were run on a 
5% non-denaturing polyacrylamide gel which was then dried and exposed to film.
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Figure 2. The methylated SM MHC GC repressor binds RBPJ
A) The indicated oligonucleotide probes were incubated with SMC nuclear extracts +/− an 
antibody for RBPJ. After 30 min, reactions were run on a 5% non-denaturing 
polyacrylamide gel which was then dried and exposed to film. ns, non-specific band. B) The 
indicated non-radiolabeled competitor oligonucleotide was added in increasing 
concentrations to gel shift reactions containing the methylated GC repressor probe and SMC 
nuclear extracts.
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Figure 3. Analysis of the RBPJ-DNA binding complex
A) Gel shift analysis of RBPJ binding to fully and hemi-methylated GC-repressor probes. B) 
Comparison between consensus and GC repressor RBPJ binding sites and thymine and 
methylated-cytosine structures. C) Gel shift reactions using the indicated variant of the GC 
repressor or consensus RBPJ probes. Please see Materials and Methods for full 
oligonucleotide sequences. D) Wt and E63D RBPJ variants were expressed in vitro and used 
in gel shift reactions with Wt and methylated (T to Cm) consensus RBPJ probes. Note equal 
expression of each RBPJ variant as measured by Western blotting for the flag epitope.
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Figure 4. RBPJ inhibits SM MHC promoter activity
A) 10T1/2 cells were transfected with SM22, SM α-actin, SM22 or minimal thymidine 
kinase (TK) reporter/luciferase constructs +/− myocardin and +/− RBPJ expression vectors. 
The total amount of expression vector in each well was equalized by addition of empty 
vector (ev). Luciferase activity was measured at 48 h and is expressed relative to promoter 
activity plus empty vector only (Con). * p<0.05 versus control. ** p<0.05 versus plus 
myocardin. B) Western blot and gel shift analyses demonstrating RBPJ knockdown in this 
model. C) A mutation (C to T) within the GC repressor that facilitates RBPJ binding was 
made in the context of the SM MHC promoter shown. SMC isolated from RBPJflox/flox mice 
were treated with Cre- or LacZ-expressing adenovirus for 48 h and then transfected with the 
Wt and T mutant constructs. Luciferase activity was measured at 48 h. * p<0.05 versus Wt. 
** p<0.05 versus LacZ.
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Figure 5. RBPJ binds the endogenous SM MHC repressor
A) Chromatin immunoprecipitation assays for RBPJ were performed in control and PDGF-
BB-treated SMC using primers spanning the GC repressor-containing region of the SM 
MHC promoter. B) Western Blot for RBPJ expression in mouse aortic SMC and 10T1/2 
cells treated with PDGF-BB and TGF-β. The ChIP and Western Blot results shown are 
representative of at least three independent experiments.
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Figure 6. RBPJ inhibits SMC differentiation marker gene expression in phenotypically 
modulated human SMC
A) ChIP assays for RBPJ binding to the indicated promoters in control and RBPJ 
knockdown human aortic SMC. B) RNA was isolated from control and RBPJ knockdown 
human aortic SMC that were maintained in growth media (undiff) or treated with TGF-β. 
Semi-quantitative RT PCR was performed for the indicated SMC marker genes and 
GAPDH. Results of RT-PCR using 5 and 45ng of RNA from TGF-β-treated cells are shown 
for quantification. C) ChIP assays for SRF and RNA Pol II binding in control and RBPJ 
knockdown SMC under growth or TGF-β-treated conditions. D) RT PCR of SMC marker 
gene expression in RBPJ knockdown, SRF knockdown, and RBPJ/SRF double knockdown 
human SMC under growth conditions. Notch3 binding (E) and H3K9 acetylation (F) at the 
SMC-specific promoters were measured by ChIP assay in control and RBPJ knockdown 
human aortic SMC treated with TGF-β. The RT-PCR and ChiP results shown are 
representative of at least 3 independent experiments.
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